Scholar Rock To Present New Data From SRK-181 Phase 1 DRAGON Trial At ASCO 2024 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Scholar Rock (NASDAQ:SRRK) announced promising data from its Phase 1 DRAGON trial of SRK-181 in combination with pembrolizumab, showing encouraging responses in anti-PD-(L)1 resistant patients across multiple tumor types. The data were presented at the ASCO Annual Meeting.
June 03, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scholar Rock presented promising data from its Phase 1 DRAGON trial of SRK-181, showing strong responses in anti-PD-(L)1 resistant patients. This could positively impact SRRK's stock price in the short term.
The positive data from the Phase 1 DRAGON trial, especially in heavily pretreated and anti-PD-(L)1 resistant patients, is likely to boost investor confidence and positively impact SRRK's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100